To maintain proteostasis, several cellular compartments and protein degradation systems cooperate. The endoplasmic reticulum (ER) is a cellular compartment involved in protein folding and secretion. Misfolded ER proteins are retrotranslocated across the ER membrane into the cytosol and are degraded by the proteasome, a process called ER-associated degradation.
3- Smith M.H.
- Ploegh H.L.
- Weissman J.S.
Road to ruin: targeting proteins for degradation in the endoplasmic reticulum.
However, an increase in unfolded proteins causes ER stress, resulting in the activation of the unfolded protein response, a signal transduction pathway that stimulates adaptive programs to recover homeostasis or trigger apoptosis of irreversibly damaged cells.
4The unfolded protein response: from stress pathway to homeostatic regulation.
Recent studies have revealed that ER stress plays a key role in neurodegeneration.
5Emerging roles of ER stress in the etiology and pathogenesis of Alzheimer's disease.
The ubiquitin-proteasome system is a major protein degradation pathway that is responsible for the degradation of functional, damaged, or misfolded proteins.
6Proteasomal defense of oxidative protein modifications.
,7- Amm I.
- Sommer T.
- Wolf D.H.
Protein quality control and elimination of protein waste: the role of the ubiquitin-proteasome system.
However, proteasomal activity decreases with age.
8- Chondrogianni N.
- Gonos E.S.
Proteasome dysfunction in mammalian aging: steps and factors involved.
, 9- Tonoki A.
- Kuranaga E.
- Tomioka T.
- Hamazaki J.
- Murata S.
- Tanaka K.
- Miura M.
Genetic evidence linking age-dependent attenuation of the 26S proteasome with the aging process.
, 10- Lopez-Otin C.
- Blasco M.A.
- Partridge L.
- Serrano M.
- Kroemer G.
The hallmarks of aging.
Because the proteasome plays an essential role in cellular homeostasis, an age-associated decline in proteasome function is assumed to contribute to the development of age-related pathologies and to the aging process itself.
11Role of proteasomes in disease.
Indeed, recent evidence indicates that reduced 26S proteasome assembly shortens life span and enhances neurodegeneration in
Drosophila.
9- Tonoki A.
- Kuranaga E.
- Tomioka T.
- Hamazaki J.
- Murata S.
- Tanaka K.
- Miura M.
Genetic evidence linking age-dependent attenuation of the 26S proteasome with the aging process.
Impaired proteasome function has been implicated in the pathogenesis of many neurodegenerative diseases, as either a primary cause or a secondary consequence.
12- Ciechanover A.
- Brundin P.
The ubiquitin proteasome system in neurodegenerative diseases: sometimes the chicken, sometimes the egg.
, 13- Keller J.N.
- Hanni K.B.
- Markesbery W.R.
Impaired proteasome function in Alzheimer's disease.
, 14- McNaught K.S.
- Olanow C.W.
- Halliwell B.
- Isacson O.
- Jenner P.
Failure of the ubiquitin-proteasome system in Parkinson's disease.
Previously, we established a transgenic (Tg) mouse model with decreased proteasomal chymotrypsin-like activity.
15- Tomaru U.
- Takahashi S.
- Ishizu A.
- Miyatake Y.
- Gohda A.
- Suzuki S.
- Ono A.
- Ohara J.
- Baba T.
- Murata S.
- Tanaka K.
- Kasahara M.
Decreased proteasomal activity causes age-related phenotypes and promotes the development of metabolic abnormalities.
Tg mice exhibited shortened lifespans and age-related phenotypes with the accumulation of polyubiquitinated and oxidized proteins. These mice showed retinal degeneration and were susceptible to age-related disorders, such as high-fat diet–induced hepatic steatosis and cigarette smoke–induced pulmonary emphysema.
15- Tomaru U.
- Takahashi S.
- Ishizu A.
- Miyatake Y.
- Gohda A.
- Suzuki S.
- Ono A.
- Ohara J.
- Baba T.
- Murata S.
- Tanaka K.
- Kasahara M.
Decreased proteasomal activity causes age-related phenotypes and promotes the development of metabolic abnormalities.
, 16- Ando R.
- Noda K.
- Tomaru U.
- Kamoshita M.
- Ozawa Y.
- Notomi S.
- Hisatomi T.
- Noda M.
- Kanda A.
- Ishibashi T.
- Kasahara M.
- Ishida S.
Decreased proteasomal activity causes photoreceptor degeneration in mice.
, 17- Yamada Y.
- Tomaru U.
- Ishizu A.
- Ito T.
- Kiuchi T.
- Ono A.
- Miyajima S.
- Nagai K.
- Higashi T.
- Matsuno Y.
- Dosaka-Akita H.
- Nishimura M.
- Miwa S.
- Kasahara M.
Decreased proteasomal function accelerates cigarette smoke-induced pulmonary emphysema in mice.
In the present study, using this model, we provide
in vivo evidence that decreased proteasomal function causes memory impairment with neuronal loss. The brain tissue of Tg mice demonstrated activation of ER stress–mediated apoptosis pathways, as well as an increase in p-tau, with accumulation in the neuronal cells of the hippocampus. We also provide
in vitro evidence that impaired proteasomes cause ER stress and cell death in HT-22, a murine hippocampal neuronal cell line. These data suggest that proteasome dysfunction is involved in memory impairment as a result of ER stress and hyperphosphorylation of tau, which may together constitute a common mechanism in the pathogenesis of age-related neurodegenerative diseases.
Materials and Methods
Mice and Behavioral Experiments
Tg mice expressing β5t were established as previously described.
15- Tomaru U.
- Takahashi S.
- Ishizu A.
- Miyatake Y.
- Gohda A.
- Suzuki S.
- Ono A.
- Ohara J.
- Baba T.
- Murata S.
- Tanaka K.
- Kasahara M.
Decreased proteasomal activity causes age-related phenotypes and promotes the development of metabolic abnormalities.
C57BL/6 mice were used as wild-type (WT) controls. Experiments were performed using 4- to 24-week–old mice. Mice were housed under a 12-hour light-dark cycle in climate-controlled, pathogen-free barrier facilities. Behavioral experiments used 24-week–old WT and Tg mice. An open field test was performed using a novel cage (30 × 30 × 30-cm
3 acrylic box) to evaluate locomotor activity. The illumination of the room was set to 20 lx. The total travel distance and the total number of crosses across 5 × 5-cm squares were monitored for 30 minutes. An elevated plus-maze test was performed to evaluate locomotor activity and anxiety-like behavior, as described previously.
18- Ohmura Y.
- Tanaka K.F.
- Tsunematsu T.
- Yamanaka A.
- Yoshioka M.
Optogenetic activation of serotonergic neurons enhances anxiety-like behaviour in mice.
The total distance traveled in the maze and the time spent in the open arms were monitored for 10 minutes. The behavior of each mouse was captured by a charge-coupled device camera and automatically analyzed using LimeLight software version 2 (Actimetrics, Wilmette, IL). To test the pain response, mice were placed on a 54.5°C hot plate, and the latency before animals licked their hind paws or jumped was measured (hot-plate test). The cutoff time for the hot-plate test was set at 30 seconds. For the contextual fear conditioning test, each mouse was acclimated in a foot-shock box (30.5 × 24.1 × 21.0 cm; Med Associates, Inc., Fairfax, VT) for 5 minutes. After placing a mouse in the box, 5-second foot shocks (shock intensity, 0.5 mA) were administered 10 times at 25-second intervals. After the last foot shock, the mouse was returned to its home cage. At 24 and 48 hours later, each mouse was placed in the foot-shock box but without being shocked. Freezing behavior, consisting of a lack of movement (except for respiration), an arched back, and retraction of the ears, was monitored for 10 minutes to analyze fear memory retrieval. The appropriate number of samples was defined on the basis of the nature of each experiment. All animal experiments were performed at Hokkaido University Graduate School of Medicine according to the NIH’s
Guide for the Care and Use of Laboratory Animals.
19Committee for the Update of the Guide for the Care and Use of Laboratory Animals
National Research Council: Guide for the Care and Use of Laboratory Animals: Eighth Edition.
Western Blot Analysis
Tissues or cells were lysed in a buffer containing 150 mmol/L NaCl, 20 mmol/L Tris-HCl (pH 7.5), 0.2% NP-40, and 1 mmol/L dithiothreitol, and then centrifuged at 15,000 × g for 10 minutes. The supernatants (20-μg aliquots of total proteins) were subjected to SDS-PAGE and blotted onto nitrocellulose membranes. The blots were probed with antibodies and reacted with horseradish peroxidase–conjugated anti-rabbit or goat IgG (Jackson ImmunoResearch, West Grove, PA) for immunodetection. The immune complexes were visualized by enhanced chemiluminescence and analyzed by Amersham Imager 680 (Amersham, Piscataway, NJ). Antibodies for the proteasomal subunits β5t, β5i, β5, and β6 were purchased from MBL (Nagoya, Japan), Enzo Life Sciences (Plymouth Meeting, PA), Santa Cruz Biotechnology (Dallas, TX), and Abcam (Cambridge, UK), respectively. Antibodies for C/EBP homologous protein and c-Jun N-terminal kinase (JNK) were purchased from Santa Cruz Biotechnology. Antibodies against phosphorylated JNK, tau, p-tau (Ser396; PHF13), glycogen synthase kinase 3β (GSK-3β), phosphorylated GSK-3β, cyclin-dependent kinase 5 (CDK5), p35/p25, and protein kinase-like endoplasmic reticulum kinase were purchased from Cell Signaling Technology (Danvers, MA). All antibodies were used according to the manufacturers' recommendations. All information, including the dilution and organism, is available on data sheets from the relevant companies. For immunoblotting using purified proteasomes, proteasomes were enriched using the CycLex Proteasome Enrichment & Activity Assay Kit (MBL). Tissue lysates (2 mg of protein) were incubated with control resin or ubiquitin-like domain resin, and then subjected to immunodetection according to the manufacturer's instructions.
Proteasomal Activity
Proteasomes were enriched from brain tissue using the CycLex Proteasome Enrichment & Activity Assay Kit. Brain tissue lysates (1 mg of protein) were incubated with control or ubiquitin-like domain resin, and applied to a proteasomal chymotrypsin-like activity assay according to the manufacturer's instructions. All data were corrected by the purified proteasomal amount and expressed as relative fluorescence units per 1 mg protein. For analysis of the proteasomal activity in HT-22 cells, proteasome activity assay kits (Proteasome-Glo Cell-Based Assay; Promega, Madison, WI) were used according to the manufacturer's instructions. Briefly, cells were incubated with specific luminogenic proteasome substrates (Suc-LLVY-aminoluciferin for chymotrypsin-like activity; Promega), and substrate luminescence was measured by a luminometer. The number of viable cells in each well was measured by ATP measurement methods using luciferase reactions (CellTiter-Glo Luminescent Cell Viability Assay; Promega). Data were corrected for the number of viable cells and expressed as the ratio of substrate luminescence/ATP luminescence. All measurements were performed in triplicate.
Protein Analysis
Brain tissues were lysed in a buffer containing 150 mmol/L NaCl, 20 mmol/L Tris-HCl (pH 7.5), 0.2% NP-40, and 1 mmol/L dithiothreitol, and centrifuged at 15,000 × g for 10 minutes. The levels of polyubiquitinated proteins, nerve growth factor (NGF), and Aβ were quantified by enzyme-linked immunosorbent assay. Detection kits for polyubiquitinated proteins, NGF, and Aβ were provided by CycLex (Nagano, Japan), Sigma-Aldrich (St. Louis, MO), and Wako (Osaka, Japan), respectively.
Quantitative RT-PCR
Total RNA from brain tissue was isolated using an ISOGEN II kit (NIPPON GENE, Tokyo, Japan), then treated with DNase I (Invitrogen, Waltham, MA) and converted to cDNA with a GoTag 2-Step RT-qPCR System (Promega). Quantitative PCR was performed in triplicate using 75 ng cDNA, and the expression of NGF-β was analyzed by a Thermal Cycler Dice (Takara Bio, Inc., Shiga, Japan). Cycling conditions were 1 cycle at 95°C for 2 minutes, followed by 40 cycles of denaturation at 95°C for 15 seconds, annealing at 60°C for 30 seconds, and extension at 72°C for 30 seconds. The primer sequences were 5′-CAAGGACGCAGCTTTCTATACTG-3′ (forward) and 5′-CTT-CAGGGACAGAGTCTCCTTCT-3′ (reverse) for NGF-β and 5′-CT-TCCCCAACAGTGCCAA-3′ (forward) and 5′-ACTTTCAGTCAGCCCCTTTG-3′ (reverse) for 18S rRNA.
Autoradiography Study
Brain tissues were embedded in OCT compound (Sakura Finetek Japan Co, Ltd, Tokyo, Japan) and frozen in isopentane/dry ice. Frozen sections (10 μm thick) were washed with phosphate-buffered saline without calcium or magnesium and preincubated with 10 mg/mL sodium l-ascorbate in saline at room temperature. The sections were then incubated with approximately 100 kBq of [125I]iomazenil (carrier free; generously provided by Nihon Medi-Physics Co, Tokyo, Japan) for 60 minutes at room temperature. After washing and drying, the sections were exposed to a phosphor imaging plate (Fuji Photo Film Co, Ltd, Tokyo, Japan). After the exposure, the imaging plate was scanned with an FLA 7000 Bio-Imaging Analyzer (Fuji Photo Film Co, Ltd) and analyzed using Multi Gauge V3.0 (Fuji Photo Film Co, Ltd). To verify the specific binding of [125I]iomazenil, sections were preincubated with 10 mmol/L clonazepam in 10 mg/mL sodium l-ascorbate with saline. Data were evaluated in terms of relative values, with the mean intensity of WT controls set at 1.
Histologic and Immunohistochemical Analysis
Formalin-fixed brain tissues were embedded in paraffin, and sections (6-μm thick) were stained with hematoxylin and eosin. Histologic images of five randomly selected fields in the hippocampal CA1 region were captured, and numbers of neuronal cells in squares of 500 × 500 μm were counted by three different experimenters (U.T., T.I., and A.I.), all of whom were blinded to group allocation. For immunohistochemistry, tissue slides were processed for antigen retrieval by a standard microwave-heating technique, then incubated with antibodies and detected with streptavidin-biotin–horseradish peroxidase. Antibodies against ubiquitin, p-tau, and Aβ were purchased from Dako (Tokyo, Japan), Abcam, and Cell Signaling Technology, respectively. Apoptotic cells in brain tissues were detected by the terminal deoxynucleotidyl transferase-mediated dUTP nick-end labeling method with an In Situ Apoptosis Detection Kit (Takara Bio, Inc.) according to the manufacturer's instructions.
Cell Culture and Detection of Cell Death
HT-22 is a murine hippocampal neuronal cell line. HT-22 cells, which were kindly provided by Dr. David Schubert (Salk Institute, La Jolla, CA), were grown in Dulbecco’s modified Eagle’s medium supplemented with 20% fetal bovine serum, 100 U/mL penicillin, and 100 U/mL streptomycin in an atmosphere of 5% CO
2 and 95% O
2 at 37°C. Equivalent numbers (1.0 to 5.0 × 10
5) of HT-22 cells were plated and treated with MG-132 (12.5 to 50.0 μmol/L)–containing Dulbecco’s modified Eagle’s medium with supplements for 24 hours. For treatment with the JNK inhibitor SP600125 or cigarette smoke extract (CSE), cells were incubated with MG-132 and 100 nmol/L SP600125 or 3.5% CSE for 24 hours. CSE was prepared as previously described.
17- Yamada Y.
- Tomaru U.
- Ishizu A.
- Ito T.
- Kiuchi T.
- Ono A.
- Miyajima S.
- Nagai K.
- Higashi T.
- Matsuno Y.
- Dosaka-Akita H.
- Nishimura M.
- Miwa S.
- Kasahara M.
Decreased proteasomal function accelerates cigarette smoke-induced pulmonary emphysema in mice.
,20- Asano H.
- Horinouchi T.
- Mai Y.
- Sawada O.
- Fujii S.
- Nishiya T.
- Minami M.
- Katayama T.
- Iwanaga T.
- Terada K.
- Miwa S.
Nicotine- and tar-free cigarette smoke induces cell damage through reactive oxygen species newly generated by PKC-dependent activation of NADPH oxidase.
For non-treated controls, phosphate-buffered saline and normal medium were used. The number of viable cells in each well was measured by ATP measurement methods using luciferase reactions (CellTiter-Glo Luminescent Cell Viability Assay; Promega). All measurements were performed in triplicate.
Image Analysis
Western blot data were subjected to image analysis using ImageJ software version 1.53e (NIH, Bethesda, MD;
https://imagej.nih.gov/ij).
Statistical Analysis
We performed statistical analyses of two unmatched groups using the unpaired two-tailed t-test. For analysis of three or more unmatched groups, we used one-way analysis of variance with multiple comparisons/post-hoc tests. P < 0.05 was considered significant.
Discussion
The proteasome is an intracellular protease responsible for most intracellular protein degradation.
31- Coux O.
- Tanaka K.
- Goldberg A.L.
Structure and functions of the 20S and 26S proteasomes.
In particular, the proteasome degrades most oxidized, aggregated, and misfolded proteins.
6Proteasomal defense of oxidative protein modifications.
,7- Amm I.
- Sommer T.
- Wolf D.H.
Protein quality control and elimination of protein waste: the role of the ubiquitin-proteasome system.
In neurodegenerative disorders, proteasomal function was shown to be impaired in the substantia nigra in Parkinson disease
32Proteasomal function is impaired in substantia nigra in Parkinson's disease.
and in the hippocampus and parahippocampal gyrus in AD.
13- Keller J.N.
- Hanni K.B.
- Markesbery W.R.
Impaired proteasome function in Alzheimer's disease.
Therefore, the functional impairment of the proteasome is assumed to trigger neurodegenerative diseases; however, the evidence supporting this assumption has thus far been limited. In the present study, mice with reduced proteasomal activity showed memory impairment with neuronal loss. The brain tissue of Tg mice demonstrated up-regulation of ER stress–related apoptosis pathways and the hyperphosphorylation of tau in hippocampal neuronal cells. Thus, collective evidence suggests that impaired proteasomal activity induces altered proteostasis, and subsequent ER stress–mediated pathways play pivotal roles in neuronal loss.
Age-related decreases in proteasomal activity have been widely documented in many organs, including the brain, and these decreases are assumed to be involved in the aging process and the development of age-related pathologies.
8- Chondrogianni N.
- Gonos E.S.
Proteasome dysfunction in mammalian aging: steps and factors involved.
,10- Lopez-Otin C.
- Blasco M.A.
- Partridge L.
- Serrano M.
- Kroemer G.
The hallmarks of aging.
,33- Keller J.N.
- Gee J.
- Ding Q.
The proteasome in brain aging.
Sporadic AD (sAD) is the most common form of AD, and its main risk factor is aging.
34Alzheimer's disease: genes, proteins, and therapy.
Therefore, animal models that accelerate age-related physiological pathology may play a fundamental role in AD research. In this respect, mice with decreased proteasomal activity could serve as an ideal model for sAD with age-associated pathology. The present mouse model showed that the decline of proteasomal activity caused abnormal proteostasis that led to both ER stress and the hyperphosphorylation of tau. A striking finding in this model was the increase of tau and p-tau. The clearance of tau protein depends mainly on the ubiquitin-proteasome system
35Degradation of tau protein by autophagy and proteasomal pathways.
; therefore, increased tau in the brain tissue of Tg mice could be simply explained by decreased proteasomal activity. In terms of the increase of p-tau, the expression of several major kinases associated with tau hyperphosphorylation was analyzed, and only the JNK pathway was significantly activated.
JNK is a component of an ER stress–mediated apoptosis pathway and plays a critical role in the formation of NFTs by direct phosphorylation of tau.
36- Lagalwar S.
- Guillozet-Bongaarts A.L.
- Berry R.W.
- Binder L.I.
Formation of phospho-SAPK/JNK granules in the hippocampus is an early event in Alzheimer disease.
Further studies analyzing other pathways, such as oxidative stress, the mitochondrial stress response, and autophagic flux, are necessary to dissect the molecular mechanisms of the increase of p-tau. The fundamental pathology in the present model is proteasomal dysfunction, and the impairment of the proteasome causes altered proteostasis and ER stress, which are common features of many neurodegenerative diseases.
,5Emerging roles of ER stress in the etiology and pathogenesis of Alzheimer's disease.
Therefore, the linkage between the decline of proteasomal function, the activation of ER stress, and the increased hyperphosphorylation of tau may be a notable pathologic process underlying neuronal loss in the present model. Interestingly, it has been reported that the proteasomal dysfunction in the brains of patients with AD is caused by the inhibitory binding of p-tau to proteasomes.
37- Tai H.C.
- Serrano-Pozo A.
- Hashimoto T.
- Frosch M.P.
- Spires-Jones T.L.
- Hyman B.T.
The synaptic accumulation of hyperphosphorylated tau oligomers in Alzheimer disease is associated with dysfunction of the ubiquitin-proteasome system.
Myeku et al
38- Myeku N.
- Clelland C.L.
- Emrani S.
- Kukushkin N.V.
- Yu W.H.
- Goldberg A.L.
- Duff K.E.
Tau-driven 26S proteasome impairment and cognitive dysfunction can be prevented early in disease by activating cAMP-PKA signaling.
demonstrated that the accumulation of insoluble tau was associated with a decrease in the peptidase activity of 26S proteasomes in the brain. Taken together, an age-related reduction of proteasomal activity may cause a cycle in neurodegenerative diseases of decreased proteasomal activity directly causing ER stress–mediated neuronal loss and phosphorylation of tau, and the accumulation of p-tau leading to further inhibition of the ubiquitin-proteasome system. Moreover, several lifestyle habits that cause increased oxidative stress, such as smoking and a high-fat diet, are known to be risk factors for the development of AD,
39- Durazzo T.C.
- Mattsson N.
- Weiner M.W.
Alzheimer's Disease Neuroimaging Initiative: Smoking and increased Alzheimer's disease risk: a review of potential mechanisms.
,40- Edwards III, G.A.
- Gamez N.
- Escobedo Jr., G.
- Calderon O.
- Moreno-Gonzalez I.
Modifiable risk factors for Alzheimer's disease.
and may prolong the cycle of decreased proteasomal activity, ER stress, and neuronal death.
Remarkably, the brain tissue of Tg mice showed accumulation of p-tau, but no amyloid deposition or NFTs. This is likely due to differences in protein characteristics between mice and humans. For example, C57BL/6 mice produce much lower numbers of the cleaved amyloid precursor protein fragments that are most prominent in humans.
41- Hunter J.M.
- Bowers W.J.
- Maarouf C.L.
- Mastrangelo M.A.
- Daugs I.D.
- Kokjohn T.A.
- Kalback W.M.
- Luehrs D.C.
- Valla J.
- Beach T.G.
- Roher A.E.
Biochemical and morphological characterization of the AβPP/PS/tau triple transgenic mouse model and its relevance to sporadic Alzheimer's disease.
Mouse wild-type tau does not aggregate into NFTs, because it shares only 88% sequence homology with human tau. In contrast, NFTs readily form in transgenic mice expressing human tau that contains gene mutations associated with frontotemporal lobar degeneration: the most commonly used models are those that express 4R tau with P301L or P301S mutations.
42Animal models of Alzheimer's disease and frontotemporal dementia.
,43- Drummond E.
- Wisniewski T.
Alzheimer's disease: experimental models and reality.
The vast majority of experimental models of AD involve transgenic mice expressing human proteins (such as amyloid precursor protein, presenilin 1, and tau) that result in the formation of amyloid plaques and NFTs
43- Drummond E.
- Wisniewski T.
Alzheimer's disease: experimental models and reality.
,44- Sasaguri H.
- Nilsson P.
- Hashimoto S.
- Nagata K.
- Saito T.
- De Strooper B.
- Hardy J.
- Vassar R.
- Winblad B.
- Saido T.C.
APP mouse models for Alzheimer's disease preclinical studies.
; however, the pathologic development in these models is non-physiological. AD is a uniquely human disease, and various models with neuropathologic features similar to those seen in AD should be examined on the basis of their protein biology. New animal models are expected to increasingly mimic sAD in terms of physiological alterations in proteostasis, and our model may serve as an appropriate foundation in this regard.
In Tg mice, neuronal loss occurred gradually after several months, and a small number of apoptotic cells were observed in the hippocampal CA1 region. In brain tissues of patients with AD, no global neocortical nerve cell loss was found.
45- Regeur L.
- Jensen G.B.
- Pakkenberg H.
- Evans S.M.
- Pakkenberg B.
No global neocortical nerve cell loss in brains from patients with senile dementia of Alzheimer's type.
Rather, AD-related neuronal loss occurred most prominently in the hippocampus.
46- West M.J.
- Coleman P.D.
- Flood D.G.
- Troncoso J.C.
Differences in the pattern of hippocampal neuronal loss in normal ageing and Alzheimer's disease.
West et al
46- West M.J.
- Coleman P.D.
- Flood D.G.
- Troncoso J.C.
Differences in the pattern of hippocampal neuronal loss in normal ageing and Alzheimer's disease.
reported that neuronal loss was seen in the CA1 region of the hippocampi of patients with AD, but not in those of a healthy elderly group. Apoptotic cell death is a quick process, and is therefore sometimes difficult to detect in slowly progressive diseases. The lifespan of mice is different from that of humans. Although it is difficult to directly compare aging in mice and humans, sporadic apoptotic cell death may occur in the hippocampi of Tg mice as well as those of patients with AD. This sporadic neuronal death in Tg mouse model may at least partly reflect the pathogenesis of human AD.
The mechanism underlying the age-related decline in proteasomal activity is not fully understood. Interestingly, it is not a general aging phenomenon, because particular cell types and tissues are more vulnerable than others.
33- Keller J.N.
- Gee J.
- Ding Q.
The proteasome in brain aging.
In rodent neuronal tissues, decreases in proteasomal chymotrypsin-like activity are evident in the cortex, hippocampus, and spinal cord, but not in the brain stem or cerebellum.
47- Keller J.N.
- Hanni K.B.
- Markesbery W.R.
Possible involvement of proteasome inhibition in aging: implications for oxidative stress.
Several types of alterations, including a decrease in proteasome subunits, altered subunit structure, post-translational modification of the proteasome, and impaired proteasome assembly, may be involved in the decrease in proteasomal function.
33- Keller J.N.
- Gee J.
- Ding Q.
The proteasome in brain aging.
,48- Carrard G.
- Bulteau A.L.
- Petropoulos I.
- Friguet B.
Impairment of proteasome structure and function in aging.
,49- Mao L.
- Romer I.
- Nebrich G.
- Klein O.
- Koppelstatter A.
- Hin S.C.
- Hartl D.
- Zabel C.
Aging in mouse brain is a cell/tissue-level phenomenon exacerbated by proteasome loss.
It appears that proteasome activation may have a beneficial effect in the prevention and treatment of neurodegenerative diseases. It has been reported that direct cellular delivery of proteasomes can delay the aggregation of tau protein.
50- Han D.H.
- Na H.K.
- Choi W.H.
- Lee J.H.
- Kim Y.K.
- Won C.
- Lee S.H.
- Kim K.P.
- Kuret J.
- Min D.H.
- Lee M.J.
Direct cellular delivery of human proteasomes to delay tau aggregation.
However, this issue is still being investigated, and there is insufficient information on the adverse effects of drugs that effectively activate proteasomes. Because decreased proteasome function impairs the cellular response to stress, drugs that prevent stress-induced neuronal death may be useful. In the present study, the JNK inhibitor SP600125 prevented the death of HT-22 cells caused by proteasomal inhibition, suggesting that JNK activation is a key pathway responsible for neuronal death. Alterations of the JNK pathway are potentially associated with pathogenesis and neuronal death in AD.
51- Yarza R.
- Vela S.
- Solas M.
- Ramirez M.J.
c-Jun N-terminal kinase (JNK) signaling as a therapeutic target for Alzheimer's disease.
Therefore, drugs capable of inhibiting the JNK pathway are an attractive therapeutic strategy. Recently, both the pharmaceutical industry and academia have devoted considerable effort to investigating such drugs; however, it is not yet possible to directly inhibit JNK isoforms in specific tissues. Newer compounds, including kinase inhibitors and peptide inhibitors that bind to the JNK binding domain, are being developed with increasing specificity for JNK inhibition.
51- Yarza R.
- Vela S.
- Solas M.
- Ramirez M.J.
c-Jun N-terminal kinase (JNK) signaling as a therapeutic target for Alzheimer's disease.
,52- Uitdehaag J.C.
- Verkaar F.
- Alwan H.
- de Man J.
- Buijsman R.C.
- Zaman G.J.
A guide to picking the most selective kinase inhibitor tool compounds for pharmacological validation of drug targets.
In conclusion, the Tg model described herein demonstrates the direct significance of in vivo proteasomal activity in the initiation and progression of neurodegenerative diseases. Our results suggest that the age-related decline in proteasomal activity plays a vital role in the accumulation of p-tau and neuronal loss. Future studies are needed to address the molecular mechanisms underlying proteasomal impairment with age, and to identify specific substrate proteins whose altered expression contributes to the development of neurodegenerative diseases. Such studies may provide a new approach to the prevention and treatment of sAD, the most common form of dementia worldwide.
Article Info
Publication History
Accepted:
October 6,
2020
Footnotes
Supported in part by Japan Society for the Promotion of Science Grant-in-Aid for Scientific Research 18H02629 (U.T.); and Smoking Research Foundation grant 2018G008 (U.T.).
Disclosures: None declared.
Copyright
© 2021 American Society for Investigative Pathology. Published by Elsevier Inc.